healthcare

Is the Sage Therapeutics Implosion Overblown?

Sage Therapeutics Inc. (NASDAQ: SAGE) shareholders took a bath on Thursday after results from its late-stage major depressive disorder (MDD) trial came public. Despite shares getting more than halved in ...
Read Full Story »

Thursday’s Biggest Biotech Movers

Thursday was a breakout day for a few biotech companies. Some made absolutely massive runs, while others fell off a cliff. The biotechnology sector is pushing near all-time highs, and ...
Read Full Story »

Why This Transfusion-Dependent Beta-Thalassemia Trial Is Taking Off

Protagonist Therapeutics Inc. (NASDAQ: PTGX) shares jumped on Wednesday after the company announced preliminary results from its midstage study for patients with transfusion-dependent beta-thalassemia. Specifically, the results come from the ...
Read Full Story »

Are Audentes Shareholders Getting Enough in the Acquisition?

Audentes Therapeutics Inc. (NASDAQ: BOLD) shares more than doubled on Tuesday after the firm announced that it would be acquired by Astellas. Although Audentes has only been public for just ...
Read Full Story »

How Aslan Pharma Is Capitalizing on Its Huge Atopic Dermatitis Success

Aslan Pharmaceuticals Ltd. (NASDAQ: ASLN) has been on a roller coaster for the past two weeks. Shares were less than $0.50 apiece in November, and only yesterday shares peaked at ...
Read Full Story »

Why Mixed Results From This Chronic Kidney Disease Study Aren’t That Great

Cara Therapeutics Inc. (NASDAQ: CARA) shares were crushed on Tuesday after the firm announced results from its midstage trial in patients with chronic kidney disease. Specifically, the results come from ...
Read Full Story »

Why Investors Shouldn’t Sleep on This Narcolepsy Study

Axsome Therapeutics Inc. (NASDAQ: AXSM) shares jumped early on Tuesday after the firm announced positive results from its midstage narcolepsy trial. Specifically, the results come from the Phase 2 Concert ...
Read Full Story »

Why This Atopic Dermatitis Study Was So Well Received

Aslan Pharmaceuticals Ltd. (NASDAQ: ASLN) shares jumped on Monday after the firm announced positive preliminary data from the lowest dose cohort of its ongoing multiple ascending dose study of ASLAN004 ...
Read Full Story »

Why This Seizure Treatment Could Be the Next Big Thing

Aquestive Therapeutics Inc. (NASDAQ: AQST) shares jumped early on Monday after the firm announced the completion of its rolling submission of a New Drug Application (NDA) to the U.S. Food ...
Read Full Story »

Major Biopharma Catalysts on the December FDA Calendar

Companies in the biotech and pharmaceutical industries are subject to a sizable amount of risk with regards to their drug candidates passing clinical trials and gaining regulatory approval. But with ...
Read Full Story »

Big Pharma Short Sellers Hike Their Bets

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Short Sellers Run For Cover From Major Biotechs

The short interest data are out for the most recent settlement date, November 15. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big ...
Read Full Story »

What This Study For ANCA Vasculitis Means Going Forward

ChemoCentryx, Inc. (NASDAQ: CCXI) shares more than tripled on Tuesday after the firm, in conjunction with Vifor Fresenius Medical Care Renal Pharma, announced positive topline data from its late-stage trial ...
Read Full Story »

Why This Newly FDA Approved Sickle Cell Treatment Will Be Huge

Global Blood Therapeutics, Inc. (NASDAQ: GBT) shares jumped on Tuesday after the firm announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Oxbryta (voxelotor) tablets ...
Read Full Story »

Novartis Finally Comes Through With Its Acquisition of Medicines Co

Medicines Co. (NASDAQ: MDCO) shares shot up on Monday after it was reported that Novartis A.G. (NYSE: NVS) will be acquiring the firm. The transaction was unanimously approved by the ...
Read Full Story »